Spero Therapeutics, Inc. Operating Expenses
Spero Therapeutics, Inc. (SPRO) reported Operating Expenses of $9.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Spero Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $9.93M, a 40.32% decline year-over-year.
- Spero Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $7.80M, a 62.16% decline year-over-year.
- Spero Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $9.89M, a 73.10% decline year-over-year.
- Spero Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $13.36M, a 58.34% decline year-over-year.
- Spero Therapeutics, Inc. operating expenses for fiscal 2025 was $60.49M, a 50.15% decline from fiscal 2024.
- Spero Therapeutics, Inc. operating expenses for fiscal 2024 was $121.34M, a 47.43% increase from fiscal 2023.
- Spero Therapeutics, Inc. operating expenses for fiscal 2023 was $82.30M, a 14.01% decline from fiscal 2022.
- Spero Therapeutics, Inc. operating expenses for fiscal 2022 was $95.71M, a 9.90% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.93M 10-Q · filed 2026-08-12 | $17.72M 10-Q · filed 2026-08-12 | $27.61M derived: sum of 3 quarters · filed 2026-08-12 | $40.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $7.80M 10-Q · filed 2026-05-13 | $17.69M derived: sum of 2 quarters · filed 2026-05-13 | $31.05M derived: sum of 3 quarters · filed 2026-05-13 | $47.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $23.25M derived: sum of 2 quarters · filed 2026-03-26 | $39.88M derived: sum of 3 quarters · filed 2026-08-12 | $60.49M 10-K · filed 2026-03-26 |
| 2025-09-30 | $13.36M 10-Q · filed 2025-11-13 | $29.99M derived: sum of 2 quarters · filed 2026-08-12 | $50.60M 10-Q · filed 2025-11-13 | $87.36M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $16.63M 10-Q · filed 2026-08-12 | $37.24M 10-Q · filed 2026-08-12 | $74.01M derived: sum of 3 quarters · filed 2026-08-12 | $106.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $20.61M 10-Q · filed 2026-05-13 | $57.37M derived: sum of 2 quarters · filed 2026-05-13 | $89.44M derived: sum of 3 quarters · filed 2026-05-13 | $118.69M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $36.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $68.83M derived: sum of 2 quarters · filed 2026-03-26 | $98.09M derived: sum of 3 quarters · filed 2026-03-26 | $121.34M 10-K · filed 2026-03-26 |
| 2024-09-30 | $32.06M 10-Q · filed 2025-11-13 | $61.32M derived: sum of 2 quarters · filed 2025-11-13 | $84.57M 10-Q · filed 2025-11-13 | $107.56M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $29.26M 10-Q · filed 2025-08-12 | $52.51M 10-Q · filed 2025-08-12 | $75.50M derived: sum of 3 quarters · filed 2025-08-12 | $102.90M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $23.25M 10-Q · filed 2025-05-13 | $46.24M derived: sum of 2 quarters · filed 2025-05-13 | $73.65M derived: sum of 3 quarters · filed 2025-05-13 | $89.25M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $22.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $50.40M derived: sum of 2 quarters · filed 2025-03-27 | $66.00M derived: sum of 3 quarters · filed 2025-03-27 | $82.30M 10-K · filed 2025-03-27 |
| 2023-09-30 | $27.41M 10-Q · filed 2024-11-14 | $43.01M derived: sum of 2 quarters · filed 2024-11-14 | $59.31M 10-Q · filed 2024-11-14 | $80.83M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $15.61M 10-Q · filed 2024-08-05 | $31.90M 10-Q · filed 2024-08-05 | $53.42M derived: sum of 3 quarters · filed 2024-08-05 | $67.26M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $16.30M 10-Q · filed 2024-05-15 | $37.81M derived: sum of 2 quarters · filed 2024-05-15 | $51.65M derived: sum of 3 quarters · filed 2024-05-15 | $79.73M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $21.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $35.36M derived: sum of 2 quarters · filed 2024-03-13 | $63.43M derived: sum of 3 quarters · filed 2024-03-13 | $95.71M 10-K · filed 2024-03-13 |
| 2022-09-30 | $13.84M 10-Q · filed 2023-11-13 | $41.91M derived: sum of 2 quarters · filed 2023-11-13 | $74.19M 10-Q · filed 2023-11-13 | $104.44M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $28.07M 10-Q · filed 2023-08-10 | $60.35M 10-Q · filed 2023-08-10 | $90.59M derived: sum of 3 quarters · filed 2023-08-10 | $116.18M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $32.28M 10-Q · filed 2023-05-11 | $62.52M derived: sum of 2 quarters · filed 2023-05-11 | $88.11M derived: sum of 3 quarters · filed 2023-05-11 | $111.80M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $30.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $55.83M derived: sum of 2 quarters · filed 2023-03-30 | $79.52M derived: sum of 3 quarters · filed 2023-03-30 | $106.23M 10-K · filed 2023-03-30 |
| 2021-09-30 | $25.59M 10-Q · filed 2022-11-14 | $49.28M derived: sum of 2 quarters · filed 2022-11-14 | $75.98M 10-Q · filed 2022-11-14 | $96.68M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $23.69M 10-Q · filed 2022-08-10 | $50.39M 10-Q · filed 2022-08-10 | $71.10M derived: sum of 3 quarters · filed 2022-08-10 | $94.11M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $26.70M 10-Q · filed 2022-05-16 | $47.41M derived: sum of 2 quarters · filed 2022-05-16 | $70.42M derived: sum of 3 quarters · filed 2022-05-16 | $90.62M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $43.72M derived: sum of 2 quarters · filed 2022-03-31 | $63.92M derived: sum of 3 quarters · filed 2022-03-31 | $88.44M 10-K · filed 2022-03-31 |
| 2020-09-30 | $23.02M 10-Q · filed 2021-11-10 | $43.22M derived: sum of 2 quarters · filed 2021-11-10 | $67.74M 10-Q · filed 2021-11-10 | $97.25M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $20.20M 10-Q · filed 2021-08-05 | $44.73M 10-Q · filed 2021-08-05 | $74.24M derived: sum of 3 quarters · filed 2021-08-05 | $96.87M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $24.52M 10-Q · filed 2021-05-06 | $54.03M derived: sum of 2 quarters · filed 2021-05-06 | $76.66M derived: sum of 3 quarters · filed 2021-05-06 | $92.47M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $29.51M 10-K · filed 2020-03-16 | $52.14M derived: sum of 2 quarters · filed 2020-11-05 | $67.95M derived: sum of 3 quarters · filed 2020-11-05 | $81.36M 10-K · filed 2021-03-11 |
| 2019-09-30 | $22.63M 10-Q · filed 2020-11-05 | $38.44M derived: sum of 2 quarters · filed 2020-11-05 | $51.85M 10-Q · filed 2020-11-05 | $64.63M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $15.81M 10-Q · filed 2020-08-06 | $29.22M 10-Q · filed 2020-08-06 | $42.00M derived: sum of 3 quarters · filed 2020-08-06 | $53.59M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $13.41M 10-Q · filed 2020-05-08 | $26.19M derived: sum of 2 quarters · filed 2020-05-08 | $37.78M derived: sum of 3 quarters · filed 2020-05-08 | $48.22M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $12.78M 10-K · filed 2020-03-16 | $24.37M derived: sum of 2 quarters · filed 2020-03-16 | $34.80M derived: sum of 3 quarters · filed 2020-03-16 | $46.77M 10-K · filed 2020-03-16 |
| 2018-09-30 | $11.59M 10-K · filed 2020-03-16 | $22.03M derived: sum of 2 quarters · filed 2020-03-16 | $34.00M 10-Q · filed 2019-11-04 | $48.99M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $10.43M 10-K · filed 2020-03-16 | $22.40M 10-Q · filed 2019-08-08 | $37.40M derived: sum of 3 quarters · filed 2020-03-16 | $47.96M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $11.97M 10-K · filed 2020-03-16 | $26.96M derived: sum of 2 quarters · filed 2020-03-16 | $37.52M derived: sum of 3 quarters · filed 2020-03-16 | $47.94M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $14.99M 10-K · filed 2019-03-14 | $25.56M derived: sum of 2 quarters · filed 2019-03-14 | $35.97M derived: sum of 3 quarters · filed 2019-03-14 | $43.71M 10-K · filed 2019-03-14 |
| 2017-09-30 | $10.56M 10-K · filed 2019-03-14 | $20.98M derived: sum of 2 quarters · filed 2019-03-14 | $28.72M 10-Q · filed 2018-11-08 | $37.86M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $10.41M 10-K · filed 2019-03-14 | $18.15M 10-Q · filed 2018-08-09 | $27.30M derived: sum of 3 quarters · filed 2019-03-14 | $35.21M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | $7.74M 10-K · filed 2019-03-14 | $16.88M derived: sum of 2 quarters · filed 2019-03-14 | $24.80M derived: sum of 3 quarters · filed 2019-03-14 | $32.88M derived: sum of 4 quarters · filed 2019-03-14 |
| 2016-12-31 | $9.14M 10-K · filed 2018-04-02 | $17.06M derived: sum of 2 quarters · filed 2018-04-02 | $25.14M derived: sum of 3 quarters · filed 2018-04-02 | $33.56M 10-K · filed 2019-03-14 |
| 2016-09-30 | $7.91M 10-K · filed 2018-04-02 | $15.99M derived: sum of 2 quarters · filed 2018-04-02 | $24.41M 10-Q · filed 2017-12-14 | |
| 2016-06-30 | $8.08M 10-K · filed 2018-04-02 | $16.50M derived: sum of 2 quarters · filed 2018-04-02 | ||
| 2016-03-31 | $8.42M 10-K · filed 2018-04-02 | |||
| 2015-12-31 | $13.33M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |